Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Analyst expectations for where Amazon stock is headed vary, but Wall Street remains optimistic overall, especially in the ...

Demand for Big Data services is increasing. Palantir, a leader in the field, should benefit. Here are the forecasts and price ...

Adaptimmune (NASDAQ:ADAP) is scheduled to announce Q1 earnings results on Tuesday, May 13th, after market close. The consensus EPS Estimate is -$0.17 and the consensus Revenue Estimate is $6.55M (+14.

Q1 2025 Management View CEO Tom Pike reported that "our revenues and adjusted EBITDA came in just about where we expected and we are reaffirming our guidance." Pike highlighted a 1.02 times ...